10x Genomics, Inc. (NASDAQ:TXG) Insider Benjamin J. Hindson Sells 4,573 Shares

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

10x Genomics Price Performance

Shares of NASDAQ TXG traded up $0.54 during mid-day trading on Wednesday, hitting $11.65. The company had a trading volume of 3,013,689 shares, compared to its average volume of 2,633,405. 10x Genomics, Inc. has a 12 month low of $10.63 and a 12 month high of $48.42. The firm has a market cap of $1.42 billion, a P/E ratio of -7.66 and a beta of 1.85. The business’s 50-day simple moving average is $14.16 and its 200-day simple moving average is $16.95.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, sell-side analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on TXG. Barclays decreased their target price on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Morgan Stanley cut their target price on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Stifel Nicolaus reduced their price target on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $20.57.

Institutional Investors Weigh In On 10x Genomics

Several institutional investors and hedge funds have recently bought and sold shares of TXG. FMR LLC raised its position in 10x Genomics by 0.6% in the fourth quarter. FMR LLC now owns 13,454,434 shares of the company’s stock worth $193,206,000 after purchasing an additional 86,455 shares in the last quarter. ARK Investment Management LLC grew its stake in shares of 10x Genomics by 11.1% in the 4th quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock valued at $171,517,000 after purchasing an additional 1,193,712 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of 10x Genomics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after buying an additional 230,145 shares in the last quarter. RA Capital Management L.P. acquired a new position in shares of 10x Genomics in the 4th quarter worth approximately $47,092,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of 10x Genomics by 10.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company’s stock worth $30,394,000 after buying an additional 193,588 shares during the period. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.